{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:11Z","timestamp":1792417391562,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder with a grave prognosis. Gene replacement therapy has significantly altered the disease trajectory. This study presents real-world evidence of the efficacy and safety of onasemnogene abeparvovec (OA) in children below 2 years of age from India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-centre, prospective cohort study includes longitudinal data of patients treated with OA for over 18 months. All patients diagnosed with SMA under 2 years of age were enrolled for OA through either the Global Managed Access Program or via commercial procurement. Once selected, patients were admitted for OA infusion, with close monitoring for adverse effects and blood parameters. Patients were followed prospectively to assess motor milestones and functional motor scores, ventilator and feeding support requirements, and hospitalization frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen children received OA over the study period. Three died within a month\u2014two likely due to the severity of the underlying disease and one from an unknown cause. Transaminitis and transient thrombocytopenia were frequently observed but managed successfully. Most patients showed gains in motor milestones during follow-up; the remainder maintained their baseline. No new ventilatory or feeding support was required. One child was weaned from permanent ventilation and gastrostomy to predominantly oral feeding, and another transitioned from nasogastric to oral feeds. Caregivers reported clinically meaningful improvement in 50% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>OA has transformed the landscape for children with early-onset SMA, enabling the achievement of motor milestones previously considered unattainable. However, the chronic nature of the disease necessitates long-term multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_861_25","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:00:14Z","timestamp":1776402014000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Onasemnogene Abeparvovec in Early-Onset Spinal Muscular Atrophy: An Indian Experience"],"prefix":"10.4103","volume":"29","author":[{"given":"Neelu","family":"Desai","sequence":"first","affiliation":[{"name":"Department of Paediatric Neurology, PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saheli","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology, PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franzina","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Kasar","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, PD Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India"},{"name":"Seth GS Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Mercuri","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","article-title":"Clinical experience with gene therapy in older patients with spinal muscular atrophy","volume":"118","author":"Matesanz","year":"2021","journal-title":"Pediatr Neurol"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: Safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/aian.aian_670_24","article-title":"Evaluating therapeutic outcomes in spinal muscular atrophy: An Indian experience","volume":"28","author":"Mohanlal","year":"2025","journal-title":"Ann Indian Acad Neurol"},{"key":"R14-20261019","first-page":"501","article-title":"Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: Safety and efficacy in the real world","volume":"5","author":"Mercuri","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care;medications, supplements and immunizations;other organ systems;and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children's hospital of philadelphia infant test of neuromuscular disorders (CHOP INTEND): Test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R17-20261019","first-page":"693","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"NeuromusculDisord"},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12955-021-01813-w","article-title":"Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy","volume":"19","author":"Staunton","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: Comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"R20-20261019","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13023-024-03326-3","article-title":"Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: Experience of the French cohort in the first three years of treatment","volume":"19","author":"Desguerre","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-024-05886-9","article-title":"Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: National real-world cohort study","volume":"184","author":"Lavie","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R22-20261019","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: An Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R23-20261019","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ppul.26285","article-title":"A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy","volume":"58","author":"AlNaimi","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"R24-20261019","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"R25-20261019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"R26-20261019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Treatment, rehabilitation, and preventive care","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"R27-20261019","first-page":"1207","article-title":"Changes in ventilatory support requirements of spinal muscular atrophy patients post gene-based therapies","volume":"9","author":"Panagiotou","year":"2022","journal-title":"Children (Basel)"},{"key":"R28-20261019","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of Onasemnogene Abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"R29-20261019","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","article-title":"Treatment of spinal muscular atrophy with onasemnogene abeparvovec in Switzerland: A prospective observational case series study","volume":"23","author":"Stettner","year":"2023","journal-title":"BMC Neurol"},{"key":"R30-20261019","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_861_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:01:29Z","timestamp":1792414889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_861_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_861_25","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-08-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}